[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]

[Oral](/topic/oral)

### Sentiment: XX%
![Sentiment Line Chart](https://lunarcrush.com/gi/w:600/t:oral/c:line/m:sentiment/iv:1d.svg)  
[Sentiment 24-Hour Time-Series Raw Data](/topic/oral/time-series/sentiment.tsv)  
**Current Value**: XX%  
**Daily Average**: XX%  
**1 Week**: XX% -X%  
**1 Month**: XX% +2%  
**6 Months**: XX% -X%  
**1 Year**: XX% +13%  
**1-Year High**: XX% on 2025-01-24  
**1-Year Low**: XX% on 2025-01-01  

**Most Supportive Themes**
- **Novo Nordisk's oral Wegovy pill:** (35%) Novo Nordisk's oral Wegovy pill shows positive weight loss results in a new study, generating significant engagement.
- **Viking Therapeutics Oral Data:** (20%) Positive results from Viking Therapeutics' oral VK2735 trial for weight loss are being discussed.
- **Supreme Court and Tariffs:** (15%) The Supreme Court's decision to expedite the review of President Trump's tariffs is a major topic.
  
**Most Critical Themes**
- **Novo Nordisk GLP-1 Concerns:** (10%)  Concerns about the tolerability and delivery issues of oral GLP-1 drugs, particularly Novo Nordisk's offerings, are being raised.
- **Hims & Hers Risks:** (5%)  While the expansion is positive, there are concerns about regulatory and competitive risks for Hims & Hers.
  
Network engagement breakdown:  
| Network | Positive  | %   | Neutral   | %   | Negative | %  |
| ------- | --------  | -   | -------   | -   | -------- | -  |
| TikTok  | XXXXXXX   | XX% | XXXXXXX   | X%  | XXXXXXX  | X% |
| X       | XXXXXXX   | X%  | XXXXXXX   | X%  | XXXXXX   | X% |
| YouTube | XXXXXXXXX | XX% | XXXXXXXXX | XX% | XXXXXXX  | X% |
| Reddit  | XXXXX     | X%  | XXXXX     | X%  | XXXXX    | X% |
| News    | XXXXXX    | X%  | XXXXX     | X%  | XXXXX    | X% |
|         |           |     |           |     |          |    |
| Total   | XXXXXXXXX | XX% | XXXXXXXXX | XX% | XXXXXXX  | X% |